CONTEXT: We have previously reported that teriparatide is associated with substantial increases in bone mineral density (BMD) at the lumbar spine (LS), total hip (TH), and femoral neck (FN) and small declines at the distal radius in 41 premenopausal women with idiopathic osteoporosis (IOP), all severely affected with low trauma fractures and/or very low BMD. Effects of teriparatide dissipate if not followed by antiresorptives. OBJECTIVE: To assess the effects of 12 and 24 months of denosumab in premenopausal women with IOP completing 24 months of teriparatide. METHODS: This was a preplanned phase 2B extension study. Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months. The main outcome measure was within-group change in BMD at the LS at 12 months. Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs). RESULTS: After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 ± 2.6% and 6.9 ± 2.6%), TH (2.9 ± 2.4% and 4.6 ± 2.8%), and FN (3.0 ± 3.8% and 4.7 ± 4.9%). Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 ± 7.8% at the LS, 9.8 ± 4.6% at the TH, and 9.5 ± 4.7% at the FN (all P < .0001). TBS increased by 5.8 ± 5.6% (P < .001). Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of denosumab. Denosumab was generally well tolerated. CONCLUSION: These data support the use of sequential teriparatide and denosumab to increase BMD in premenopausal women with severe osteoporosis.
CONTEXT: We have previously reported that teriparatide is associated with substantial increases in bone mineral density (BMD) at the lumbar spine (LS), total hip (TH), and femoral neck (FN) and small declines at the distal radius in 41 premenopausal women with idiopathic osteoporosis (IOP), all severely affected with low trauma fractures and/or very low BMD. Effects of teriparatide dissipate if not followed by antiresorptives. OBJECTIVE: To assess the effects of 12 and 24 months of denosumab in premenopausal women with IOP completing 24 months of teriparatide. METHODS: This was a preplanned phase 2B extension study. Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months. The main outcome measure was within-group change in BMD at the LS at 12 months. Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs). RESULTS: After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 ± 2.6% and 6.9 ± 2.6%), TH (2.9 ± 2.4% and 4.6 ± 2.8%), and FN (3.0 ± 3.8% and 4.7 ± 4.9%). Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 ± 7.8% at the LS, 9.8 ± 4.6% at the TH, and 9.5 ± 4.7% at the FN (all P < .0001). TBS increased by 5.8 ± 5.6% (P < .001). Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of denosumab. Denosumab was generally well tolerated. CONCLUSION: These data support the use of sequential teriparatide and denosumab to increase BMD in premenopausal women with severe osteoporosis.
Authors: Adi Cohen; Mafo Kamanda-Kosseh; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Serge Cremers; Mariana Bucovsky; Julie Stubby; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2015-09-10 Impact factor: 5.958
Authors: Christian Muschitz; Roland Kocijan; Judith Haschka; Dieter Pahr; Alexandra Kaider; Peter Pietschmann; Didier Hans; Gabriela Katharina Muschitz; Astrid Fahrleitner-Pammer; Heinrich Resch Journal: Bone Date: 2015-06-16 Impact factor: 4.398
Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: B L Langdahl; F Marin; E Shane; H Dobnig; J R Zanchetta; M Maricic; K Krohn; K See; M R Warner Journal: Osteoporos Int Date: 2009-04-07 Impact factor: 4.507
Authors: Eugene V McCloskey; Anders Odén; Nicholas C Harvey; William D Leslie; Didier Hans; Helena Johansson; Reinhard Barkmann; Stephanie Boutroy; Jacques Brown; Roland Chapurlat; Petra J M Elders; Yuki Fujita; Claus-C Glüer; David Goltzman; Masayuki Iki; Magnus Karlsson; Andreas Kindmark; Mark Kotowicz; Norio Kurumatani; Timothy Kwok; Oliver Lamy; Jason Leung; Kurt Lippuner; Östen Ljunggren; Mattias Lorentzon; Dan Mellström; Thomas Merlijn; Ling Oei; Claes Ohlsson; Julie A Pasco; Fernando Rivadeneira; Björn Rosengren; Elisabeth Sornay-Rendu; Pawel Szulc; Junko Tamaki; John A Kanis Journal: J Bone Miner Res Date: 2015-11-19 Impact factor: 6.741
Authors: Sanchita Agarwal; Elizabeth Shane; Thomas Lang; Stephanie Shiau; Mafo Kamanda-Kosseh; Mariana Bucovsky; Joan M Lappe; Julie Stubby; Robert R Recker; Yizhong Hu; Zexi Wang; X Edward Guo; Adi Cohen Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134
Authors: Alice Costantini; Riikka E Mäkitie; Markus A Hartmann; Nadja Fratzl-Zelman; M Carola Zillikens; Uwe Kornak; Kent Søe; Outi Mäkitie Journal: J Bone Miner Res Date: 2022-09-11 Impact factor: 6.390